Cargando…

Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration

Pentatricopeptide repeat domain 1 (PTCD1) was reported to regulate mitochondrial metabolism and oxidative phosphorylation. However, the effect and mechanism of PTCD1 in the development of bladder urothelial carcinoma (BLCA) remain unclear. The databases from The Cancer Genome Atlas (TCGA) and Human...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhongbao, Zhou, Yongjian, Zhou, Xin, Huang, Yongjin, Cui, Yuanshan, Zhang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256401/
https://www.ncbi.nlm.nih.gov/pubmed/35799606
http://dx.doi.org/10.1155/2022/1146186
_version_ 1784741104475701248
author Zhou, Zhongbao
Zhou, Yongjian
Zhou, Xin
Huang, Yongjin
Cui, Yuanshan
Zhang, Yong
author_facet Zhou, Zhongbao
Zhou, Yongjian
Zhou, Xin
Huang, Yongjin
Cui, Yuanshan
Zhang, Yong
author_sort Zhou, Zhongbao
collection PubMed
description Pentatricopeptide repeat domain 1 (PTCD1) was reported to regulate mitochondrial metabolism and oxidative phosphorylation. However, the effect and mechanism of PTCD1 in the development of bladder urothelial carcinoma (BLCA) remain unclear. The databases from The Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA) were used to analyze the expression changes, clinical features, and prognostic values of PTCD1. A nomogram was built to predict the prognostic outcomes of BLCA cases. The potential genes interacting with PTCD1 were explored by Weighted Gene Coexpression Network Analysis (WGCNA). The estimation of associations between PTCD1 and tumor mutations, tumor immunities, and m6A methylations was performed. The study found that the gradual decrease of PTCD1 expression was observed with the increase of stage and grade. Low PTCD1 expression was greatly correlated with higher pathological stage, N stage, and poor prognosis in TCGA cohorts; interestingly, low-grade BLCA cases all exhibited high expression of PTCD1. HPA database analysis implied that the expression of PTCD1 protein in BLCA was lower than that in normal bladder tissue, and the protein expression of PTCD1 in high-grade BLCA was lower than that in low-grade BLCA. Multivariate Cox regression analysis indicated that PTCD1 may serve as an independent factor influencing prognosis of BLCA. Mechanistically, PTCD1 played a regulatory role in BLCA progression through multiple tumor-related pathways containing PI3K-Akt signaling, ECM-receptor interaction, oxidative phosphorylation, and extracellular matrix organization. WGCNA reported that PTCD1 had a strong positive correlation with POLR2J, ZNHT1, ATP5MF, PDAP1, BUD31, and COPS6. Besides, the mRNA expression of PTCD1 was negatively associated with immune cells' infiltrations, immune functions, and checkpoints, especially with some m6A methylation regulators in BLCA. In sum, downregulation of PTCD1 expression may be involved in the development of BLCA and remarkably correlated with poor prognosis. Meantime, it showed an influence in immune cell infiltration and may serve as an agreeable prognostic indicator in BLCA.
format Online
Article
Text
id pubmed-9256401
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92564012022-07-06 Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration Zhou, Zhongbao Zhou, Yongjian Zhou, Xin Huang, Yongjin Cui, Yuanshan Zhang, Yong J Oncol Research Article Pentatricopeptide repeat domain 1 (PTCD1) was reported to regulate mitochondrial metabolism and oxidative phosphorylation. However, the effect and mechanism of PTCD1 in the development of bladder urothelial carcinoma (BLCA) remain unclear. The databases from The Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA) were used to analyze the expression changes, clinical features, and prognostic values of PTCD1. A nomogram was built to predict the prognostic outcomes of BLCA cases. The potential genes interacting with PTCD1 were explored by Weighted Gene Coexpression Network Analysis (WGCNA). The estimation of associations between PTCD1 and tumor mutations, tumor immunities, and m6A methylations was performed. The study found that the gradual decrease of PTCD1 expression was observed with the increase of stage and grade. Low PTCD1 expression was greatly correlated with higher pathological stage, N stage, and poor prognosis in TCGA cohorts; interestingly, low-grade BLCA cases all exhibited high expression of PTCD1. HPA database analysis implied that the expression of PTCD1 protein in BLCA was lower than that in normal bladder tissue, and the protein expression of PTCD1 in high-grade BLCA was lower than that in low-grade BLCA. Multivariate Cox regression analysis indicated that PTCD1 may serve as an independent factor influencing prognosis of BLCA. Mechanistically, PTCD1 played a regulatory role in BLCA progression through multiple tumor-related pathways containing PI3K-Akt signaling, ECM-receptor interaction, oxidative phosphorylation, and extracellular matrix organization. WGCNA reported that PTCD1 had a strong positive correlation with POLR2J, ZNHT1, ATP5MF, PDAP1, BUD31, and COPS6. Besides, the mRNA expression of PTCD1 was negatively associated with immune cells' infiltrations, immune functions, and checkpoints, especially with some m6A methylation regulators in BLCA. In sum, downregulation of PTCD1 expression may be involved in the development of BLCA and remarkably correlated with poor prognosis. Meantime, it showed an influence in immune cell infiltration and may serve as an agreeable prognostic indicator in BLCA. Hindawi 2022-06-28 /pmc/articles/PMC9256401/ /pubmed/35799606 http://dx.doi.org/10.1155/2022/1146186 Text en Copyright © 2022 Zhongbao Zhou et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhou, Zhongbao
Zhou, Yongjian
Zhou, Xin
Huang, Yongjin
Cui, Yuanshan
Zhang, Yong
Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration
title Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration
title_full Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration
title_fullStr Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration
title_full_unstemmed Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration
title_short Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration
title_sort downregulation of ptcd1 in bladder urothelial carcinoma predicts poor prognosis and levels of immune infiltration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256401/
https://www.ncbi.nlm.nih.gov/pubmed/35799606
http://dx.doi.org/10.1155/2022/1146186
work_keys_str_mv AT zhouzhongbao downregulationofptcd1inbladderurothelialcarcinomapredictspoorprognosisandlevelsofimmuneinfiltration
AT zhouyongjian downregulationofptcd1inbladderurothelialcarcinomapredictspoorprognosisandlevelsofimmuneinfiltration
AT zhouxin downregulationofptcd1inbladderurothelialcarcinomapredictspoorprognosisandlevelsofimmuneinfiltration
AT huangyongjin downregulationofptcd1inbladderurothelialcarcinomapredictspoorprognosisandlevelsofimmuneinfiltration
AT cuiyuanshan downregulationofptcd1inbladderurothelialcarcinomapredictspoorprognosisandlevelsofimmuneinfiltration
AT zhangyong downregulationofptcd1inbladderurothelialcarcinomapredictspoorprognosisandlevelsofimmuneinfiltration